成人先天性心脏病中NT-proBNP、肌钙蛋白T与GDF-15的预后价值
该研究纳入595例临床稳定的成人先天性心脏病(ACHD)患者,中位随访42个月,评估NT-proBNP、高敏肌钙蛋白T和生长分化因子15与心血管事件的关系。结果显示NT-proBNP上四分位(>33.3 pmol/L)与心血管事件及死亡或心衰独立强相关,且能可靠排除死亡和心衰风险。
要点
- NT-proBNP>33.3 pmol/L与心血管事件风险显著增加独立相关(调整HR 9.05)。
- NT-proBNP最低两个四分位组死亡和心衰累积比例仅1%。
- NT-proBNP、hs-TnT和GDF-15升高可识别心血管事件最高危患者。
核心结论
- NT-proBNP在ACHD患者中提供超越传统风险标志物的预后信息,并能可靠排除死亡和心衰风险。
- NT-proBNP、高敏肌钙蛋白T和生长分化因子15升高可识别心血管事件最高危的ACHD患者。
研究设计与样本
- 前瞻性队列研究,纳入2011年4月至2013年4月门诊就诊的临床稳定ACHD患者595例,中位年龄33岁,58%男性,90%为NYHA I级。
- 基线进行临床评估、心电图、超声心动图和生物标志物检测,前瞻性随访心血管事件,中位随访42个月。
主要发现
- NT-proBNP上四分位(>33.3 pmol/L)与心血管事件(n=165)独立相关,调整HR 9.05(95%CI 3.24-25.3),P<0.001。
- NT-proBNP上四分位与死亡或心衰(n=50)独立相关,调整HR 16.0(95%CI 2.04-126),P<0.001。
- NT-proBNP最低两个四分位组死亡和心衰累积比例仅1%。
- NT-proBNP>14 pmol/L、高敏肌钙蛋白T>14 ng/L和GDF-15>1109 ng/L可识别心血管事件最高危患者(log-rank P<0.0001)。
关键数值与推荐
- NT-proBNP上四分位切点为>33.3 pmol/L。
- 升高的NT-proBNP定义为>14 pmol/L。
- 升高的高敏肌钙蛋白T定义为>14 ng/L。
- 升高的生长分化因子15定义为>1109 ng/L。
临床怎么用
- 在ACHD门诊监测中可检测NT-proBNP,用于风险分层并辅助排除死亡和心衰低危患者。
- 联合NT-proBNP、高敏肌钙蛋白T和GDF-15可识别需加强管理的高危ACHD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of patients with adult congenital heart disease (ACHD) is rapidly increasing. To optimize patient management, there is a great need to accurately identify high-risk patients. Still, no biomarker has been firmly established as a clinically useful prognostic tool in this group. We studied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin-T, and growth-differentiation factor 15 with cardiovascular events in ACHD. METHODS: Clinically stable patients with ACHD who routinely visited the outpatient clinic between April 2011 and April 2013 underwent clinical assessment, electrocardiography, echocardiography, and biomarker measurement (NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15) at the time of study inclusion. Patients were prospectively followed for the occurrence of cardiovascular events (death, heart failure, hospitalization, arrhythmia, thromboembolic events, and reintervention). Survival curves were derived by the Kaplan-Meier method, and Cox regression was performed to investigate the relation between biomarkers and events with adjustment for multiple clinical and echocardiographic variables. RESULTS: In total, 595 patients were included (median age, 33 years; interquartile range, 25-41 years; 58% male; 90% New York Heart Association class I). Patients were followed during a median of 42 (interquartile range, 37-46) months. Of the 3 evaluated biomarkers, NT-proBNP in the upper quartile (>33.3 pmol/L) was most strongly associated with cardiovascular events (n=165, adjusted hazard ratio, 9.05 [3.24-25.3], P<0.001) and with death or heart failure (n=50, adjusted hazard ratio, 16.0 [2.04-126], P<0.001). When NT-proBNP was analyzed as a continuous variable, similar findings were retrieved. The cumulative proportion of patients with death and heart failure was only 1% in the lowest 2 NT-proBNP quartiles. Elevated NT-proBNP (>14 pmol/L), elevated high-sensitive troponin-T (>14 ng/L), and elevated growth-differentiation factor 15 (>1109 ng/L) identified those patients at highest risk of cardiovascular events (log-rank P<0.0001). CONCLUSIONS: NT-proBNP provides prognostic information beyond a conventional risk marker model in patients with ACHD and can reliably exclude the risk of death and heart failure. Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15 identify patients at highest risk of cardiovascular events. These biomarkers therefore may play an important role in the monitoring and management of patients with ACHD.
引用
- Baggen VJ, van den Bosch AE, Eindhoven JA, et al. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease. Circulation. 2016. PMID: 27832613. doi:10.1161/CIRCULATIONAHA.116.023255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。